Halozyme Therapeutics, Inc. <HALO.O>: H.C. Wainwright Raises Target Price to $115 From $95
HALO•Related News
Kimbell Royalty Partners Q2 FY26 net income rises 77.34% to $47.3 million; revenue climbs 29.97% to $112.5 million
KRP•
Parker-Hannifin Corp <PH.N>: BMO raises target price to $1214 from $1068
PH•
Oklo announces availability of Q2 2026 financial results report and business update
OKLO•
Wendy's Q2 Adjusted EPS USD 0.18 Vs. IBES Estimate USD 0.16
WEN•
China tax authority clarifies offshore insurance income subject to domestic tax, report says
XLF•